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MicroRNA-31 functions as an oncogenic 
microRNA in mouse and human lung cancer 
cells by repressing specific tumor suppressors
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MicroRNAs	(miRNAs)	regulate	gene	expression.	It	has	been	suggested	that	obtaining	miRNA	expression	
profiles	can	improve	classification,	diagnostic,	and	prognostic	information	in	oncology.	Here,	we	sought	to	
comprehensively	identify	the	miRNAs	that	are	overexpressed	in	lung	cancer	by	conducting	miRNA	microar-
ray	expression	profiling	on	normal	lung	versus	adjacent	lung	cancers	from	transgenic	mice.	We	found	that	
miR-136,	miR-376a,	and	miR-31	were	each	prominently	overexpressed	in	murine	lung	cancers.	Real-time	
RT-PCR	and	in	situ	hybridization	(ISH)	assays	confirmed	these	miRNA	expression	profiles	in	paired	normal-
malignant	lung	tissues	from	mice	and	humans.	Engineered	knockdown	of	miR-31,	but	not	other	highlighted	
miRNAs,	substantially	repressed	lung	cancer	cell	growth	and	tumorigenicity	in	a	dose-dependent	manner.	
Using	a	bioinformatics	approach,	we	identified	miR-31	target	mRNAs	and	independently	confirmed	them	as	
direct	targets	in	human	and	mouse	lung	cancer	cell	lines.	These	targets	included	the	tumor-suppressive	genes	
large	tumor	suppressor	2	(LATS2)	and	PP2A	regulatory	subunit	B	alpha	isoform	(PPP2R2A),	and	expression	
of	each	was	augmented	by	miR-31	knockdown.	Their	engineered	repression	antagonized	miR-31–mediated	
growth	inhibition.	Notably,	miR-31	and	these	target	mRNAs	were	inversely	expressed	in	mouse	and	human	
lung	cancers,	underscoring	their	biologic	relevance.	The	clinical	relevance	of	miR-31	expression	was	further	
independently	and	comprehensively	validated	using	an	array	containing	normal	and	malignant	human	lung	
tissues.	Together,	these	findings	revealed	that	miR-31	acts	as	an	oncogenic	miRNA	(oncomir)	in	lung	cancer	
by	targeting	specific	tumor	suppressors	for	repression.
Introduction
MicroRNAs (miRNAs) are critical regulators of gene expression (1, 
2). Mature miRNAs bind target mRNAs at complementary sites 
in 3′–untranslated regions (3′-UTRs) or coding sequences and 
thereby trigger downregulation, suppressing target gene expres-
sion (3, 4). MiRNAs are differentially expressed in human can-
cers and play important roles in carcinogenesis (5). Also, miRNA 
expression profiles improve cancer classification, diagnosis, and 
clinical prognostic information (6, 7).
Lung cancer is the most common cause of cancer-related 
mortality for men and women in the United States (8). Some 
miRNAs are deregulated in lung cancers. For example, low 
expression of let-7a and high expression of miR-155 are associ-
ated with a poor clinical outcome in lung cancer (9, 10). The 
miR-34 family is also repressed in cancer and involved in p53 
tumor suppression in diverse cancers (11–16), including lung 
cancer, as our team reported (17). These findings underscored 
the need for an in-depth search for miRNAs overexpressed in 
lung carcinogenesis that play critical roles in regulating lung 
cancer growth or tumorigenicity. This was the objective of the 
present study.
Our prior work revealed a subset of miRNAs repressed in 
murine lung cancers relative to adjacent normal lung in cyclin E– 
transgenic lines and in paired human normal-malignant lung tis-
sues (17). These murine transgenic lines recapitulated frequent 
features of human lung carcinogenesis, including chromosome 
instability, hedgehog pathway activation, pulmonary dysplasia, 
and single, multiple, or metastatic lung adenocarcinomas (18). 
These models proved useful for identifying repressed miRNAs in 
murine malignant versus normal lung tissues (17). These findings 
provided a rationale for confirming similar miRNA expression 
profiles in human lung cancer (17). The present study sought to 
use these transgenic lines and a paired human normal-malignant 
lung tissue bank (17) as well as a normal lung-lung cancer tis-
sue microarray to determine miRNAs prominently overexpressed 
in lung cancers relative to adjacent normal lung tissue. It was 
hypothesized that some of these miRNAs would function as 
oncomirs (oncogenic miRNAs) and critical regulators of lung 
cancer growth or tumorigenicity.
We performed comprehensive miRNA microarray analyses on 
pulmonary adenocarcinomas versus adjacent normal lung tis-
sues in transgenic cyclin E–expressing transgenic lines (18) using 
murine and human annotated miRNAs and a previously described 
miRNA expression array (17). A novel set of overexpressed miRNAs 
was found that included miR-31, which was one of the most sub-
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stantially overexpressed miRNAs in both murine and human lung 
cancers. Real-time RT-PCR assays and in situ hybridization (ISH) 
assays were independently performed on specific highlighted 
miRNAs to confirm findings in both paired murine and human 
normal-malignant lung tissues. For assessment of the functional 
consequence of this miRNA overexpression profile, each high-
lighted miRNA was independently knocked down in murine and 
human lung cancer cell lines. Only engineered repression of miR-31 
conferred growth inhibition of these lung cancer cells.
These findings were extended to the in vivo setting by dose-
dependent knockdown of miR-31 in murine lung cancer cells 
before tail vein injections into syngeneic FVB mice. Large tumor 
suppressor 2 (Lats2) and PP2A regulatory subunit B alpha isoform 
(Ppp2r2a) were also identified bioinformatically as tumor-suppres-
sive miR-31 target mRNAs. Luciferase reporter assays revealed that 
both LATS2 and PPP2R2A were miR-31 direct targets through 
3′-UTR binding. Mechanistic evidence in support of functional 
roles for LATS2 and PPP2R2A in triggering miR-31 effects was 
found. Further evidence for the relevance of LATS2 and PPP2R2A 
expression in lung carcinogenesis came independently from stud-
ies of their expression profiles in a panel of murine and human 
lung cancers relative to adjacent normal lung tissues. These obser-
vations were validated in tissue microarray studies of lung cancer 
cases enrolled in a population-based epidemiologic study from the 
New Hampshire State Cancer Registry and the Dartmouth-Hitch-
cock Tumor Registry. Taken together, these findings indicate that 
miR-31 acts as an oncomir by repressing expression of specific 
tumor suppressors in lung cancer.
Results
Overexpression of miRNAs in murine transgenic lung cancer. To uncover 
miRNAs overexpressed in lung cancers, we conducted compre-
hensive locked nucleic acid (LNA) microarray analyses to obtain 
miRNA expression profiles independently in malignant and nor-
mal lung. Tissues were isolated from human surfactant protein C– 
driven (SP-C–driven) wild-type and proteasome degradation–
resistant cyclin E–transgenic murine lines (18). Degradation-resis-
tant cyclin E lines had a higher number of neoplastic lesions as 
compared with wild-type cyclin E lines even when cyclin E expres-
sion levels were comparable (18). Adenocarcinomas and adjacent 
normal lung tissues from these transgenic lines and normal lung 
tissues from age- and sex-matched nontransgenic (Tg–) FVB mice 
were each examined in these miRNA microarrays containing 315 
murine miRNAs. Three transgenic mice and 3 Tg– mice were inde-
pendently examined in miRNA microarray analyses. Figure 1A 
displays statistically significant expression changes of the most- 
to least-overexpressed miRNAs in these representative murine tis-
sues. Figure 1B presents the fold changes of these miRNAs rela-
tive to Tg– normal lung tissues.
These lung cancers had 114- to 4-fold higher expression levels of 
the highlighted miRNAs as compared with Tg– normal lung tissues. 
The 3 miRNAs with highest expression levels (>10 fold) in these 
lung cancers were miR-136, miR-376a, and miR-31, as shown in 
Figure 1B. All 3 miRNAs were previously unrecognized as highlight-
ed miRNAs in lung cancer. Several of the overexpressed miRNAs 
identified in this study were concordant with previously report-
ed miRNA profiles in malignant versus normal tissues (19–26). 
Of note, miR-21 expression was reported as being increased in lung 
cancer (27). As expected, miR-21 expression in transgenic lung can-
cers was much higher (5-fold) in these tumors relative to adjacent 
normal lung, as shown in Figure 1.
To independently validate and to determine spatial distribu-
tion patterns of specific miRNAs, we used ISH assays. As shown in 
Figure 2, malignant (adenocarcinoma) and adjacent normal lung 
tissues were studied in cyclin E–transgenic mice. Histopathologic 
analyses of lung tissues were performed to confirm that normal 
and malignant lung tissues were each examined. Expression pro-
files of miR-31 (the functionally highlighted miRNA), miR-21, 
and control 18S rRNA were each analyzed by ISH in malignant 
and normal lung tissues from transgenic mice. As shown, miR-31 
exhibited reduced expression in murine normal lung tissue, but 
high miR-31 expression was detected within murine malignant 
lung tissue. Concordant results were observed in human paired 
normal-malignant lung tissues, as shown in Figure 2. Low levels of 
miR-31 expression were found in normal human lung tissue, but 
a high expression level was present in malignant lung tissue. As 
anticipated from previous work (17, 27), miR-21 was also detected 
at higher expression levels in malignant than in normal human 
lung tissue (Figure 2). The 18S rRNA signal was ubiquitously 
expressed in both normal and malignant lung tissues, confirming 
Figure 1
The most prominently overexpressed miRNAs in murine transgenic lung 
cancers relative to adjacent normal lung tissues. (A) MiRNA profiling of 
lung adenocarcinomas and adjacent normal lung tissues from murine wild-
type (line 2) and degradation-resistant (line 4) cyclin E–transgenic lines. 
As shown, miR-136, miR-376a, miR-31, miR-205, miR-337, miR-410, 
miR-379, miR-127, miR-431, and miR-21 were each significantly 
overexpressed in lung adenocarcinomas versus normal lung. (B) Quan-
tification of the overexpressed miRNAs in murine lung cancers versus 
normal lung tissues in A. Error bars indicate SD. T, malignant tumor; 
Tg–, murine nontransgenic FVB normal lung tissue.
research article
1300	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 120   Number 4   April 2010
integrity of the RNA used in these tissue analyses. Together, these 
results confirmed differential expression of specific miRNAs in 
malignant versus normal lung tissues.
To validate the expression profiles of these miRNAs independently, 
we conducted real-time RT-PCR assays using total RNA isolated from 
pulmonary adenocarcinomas and adjacent normal lung tissues from 
the described murine transgenic lines. As shown, miR-136, miR-376a, 
miR-31 (Figure 3), and other miRNAs (data not shown) were each 
significantly overexpressed relative to Tg– normal lung tissues by real-
time RT-PCR assays using RNA derived from transgenic malignant 
versus normal transgenic or Tg– lung tissues. Each assay was conduct-
ed at least 3 independent times, with similar results obtained. Results 
were consistent with findings from miRNA microarray experiments 
(Figure 3A and data not shown). The findings shown in Figure 3A 
from murine lung tissues are presented, since the same miRNAs were 
also frequently overexpressed in human lung cancers versus adjacent 
normal lung tissues, as shown in Figure 3B.
Overexpression of miRNAs in human lung cancers. Since previous work 
demonstrated that expression profiles for murine tumor-suppres-
sive miRNAs were concordant with those detected in human lung 
cancers (17), it was hypothesized that augmented miRNAs identified 
in murine lung cancers would also be overexpressed in human lung 
cancers as compared with adjacent normal lung tissues. To explore 
this possibility, we examined paired human normal-malignant lung 
tissues from subsets of non–small cell lung cancers (NSCLCs: ade-
nocarcinoma, squamous cell carcinoma, large cell carcinoma, and 
bronchoalveolar carcinoma) using a previously described lung tissue 
bank (17, 28). Overexpression of miR-136, miR-376a, and miR-31 
was frequently detected in each type of NSCLC as compared with 
adjacent normal lung tissues (Figure 3B). Each of these highlighted 
miRNAs was independently examined in the indicated murine and 
human lung tissues. In contrast, the other miRNAs identified as dif-
ferentially overexpressed in murine transgenic lung cancer (Figure 1) 
were detected as overexpressed in only a minority of these NSCLC 
subtypes (data not shown). Of these differentially overexpressed 
miRNAs, miR-31 was selected for in-depth study based on the trans-
fection experiments described below.
Knockdown of miRNAs in lung cancer cells. To study whether these 
highlighted miRNAs affected lung cancer growth, we conducted 
independent experiments to engineer the miRNAs with increased 
Figure 2
ISH assays for representative overexpressed miRNAs in lung cancers. These assays were conducted on adenocarcinomas and adjacent normal 
lung tissues from cyclin E–transgenic mice and from human paired normal-malignant lung tissues. Overexpression of miR-21 and miR-31 was 
detected in malignant versus normal lung tissues. The 18S rRNA signal served as a positive control for integrity of RNA. H&E staining of the 
indicated tissue sections is shown. Original magnification, ×100.
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or decreased expression in murine lung cancer cell lines (ED-1 and 
ED-2) as well as in the murine C10 alveolar type II epithelial cell line. 
Independent overexpression of miR-136, miR-376a, and miR-31 
in these cell lines did not appreciably affect murine lung cell 
growth (data not shown). This was likely due to the high basal 
levels of these miRNAs in these respective cell lines: engineering 
them to express even higher levels did not elicit further effects. 
To confirm this, we independently conducted real-time RT-PCR 
assays in each of these cell lines as well as in murine and human 
lung cancer tissues to assess the relative levels of the miRNAs of 
interest as compared with control RNAs (small nucleolar RNA-135 
[sno-135] for murine cells and tissues and U6 small nuclear 2 RNA 
[RUN6B] for human cells and tissues). Findings revealed that 
miR-31 expression levels were higher in nearly all the cell lines 
examined (cancer and immortalized cell lines) than in the murine 
(Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI39566DS1) or human (Supple-
mental Figure 1B) lung cancer tissues.
In contrast, knockdown of miR-31 significantly reduced lung can-
cer cell growth as compared with controls, as shown in Figure 4A. 
Independent knockdown of miR-31 was achieved in murine lung 
cancer cell lines (ED-1 and ED-2) as well as in murine C10 pulmo-
nary epithelial cells. ED-1 and ED-2 cell growth was suppressed 
more than 60% (P < 0.0001), while C10 cell growth was less promi-
nently reduced (P < 0.01). An appreciable increase in apoptosis 
was not observed by knockdown of miR-31 as compared with 
controls (data not shown). Greater than 90% of cells from each 
cell line were transfected (data not shown), and miR-31 levels 
in each knockdown transfectant were reduced to less than 10% 
of the control transfectants, as confirmed by real-time RT-PCR 
assays (Figure 4A).
It was hypothesized that similar effects would be observed in 
BEAS-2B human immortalized bronchial epithelial cells versus 
human lung cancer cell lines. The same transfection experiments 
were independently conducted in H23 and H226 human lung 
cancer cell lines as well as in BEAS-2B immortalized human bron-
chial epithelial cells. A significant (P = 0.00019 for H23 cells and 
P = 0.015 for H226 cells) growth-suppressive effect was indepen-
dently caused by knockdown of miR-31 in H23 and H226 cells 
(Figure 4A). Intriguingly, proliferation of transfected BEAS-2B 
cells was not significantly affected by engineered miR-31 knock-
down, suggesting a different response to loss of miR-31 expression 
in human immortalized versus malignant lung cells. Cell cycle 
analyses were conducted on transfectants. G1 arrest was observed 
in murine and human lung cancer cell lines (data not shown).
To exclude nonspecific transfection effects and to examine 
whether this growth inhibition was reversible, miR-31 was inde-
pendently knocked down in ED-1 and ED-2 cells and growth sup-
Figure 3
Validation of miR-136, miR-376a, and miR-31 expression profiles by real-time RT-PCR assays performed on RNA isolated from the indicated 
murine cyclin E–transgenic lines and from paired human normal-malignant lung tissues. (A) Real-time RT-PCR assays for miR-136, miR-376a, 
and miR-31 were performed. T, malignant tumor; N, adjacent normal murine lung; and Tg–, murine nontransgenic FVB normal lung tissue. 
Results were normalized to expression levels detected in FVB murine Tg– lung tissues. (B) Real-time RT-PCR assays for miR-136, miR-376a, 
and miR-31 were independently performed on paired human normal-malignant lung tissues. AD, adenocarcinoma; SC, squamous cell carci-
noma; LC, large cell carcinoma; BAC, bronchoalveolar carcinoma. Results were normalized to expression levels measured in normal human 
lung. Error bars indicate SD.
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pression examined in these transfectants. Two days after the first 
transfection, pre–miR-31 or an inactive pre-miR control oligonu-
cleotide was transiently overexpressed in these cells. As expected, 
engineered overexpression of miR-31 reversed anti–miR-31–medi-
ated growth suppression (Figure 4B). The miR-31 expression lev-
els in the indicated transfectants were determined by real-time 
RT-PCR assays (Figure 4B).
Knockdown of miR-31 represses in vivo tumorigenicity. It was exam-
ined whether miR-31 inhibition would reduce clonal growth of 
lung cancer cells. This was based on the observation that miR-31 
knockdown inhibited lung cancer cellular growth. Consistent with 
the hypothesis, independent knockdown of miR-31 was found to 
significantly reduce ED-1 and ED-2 colony formation, as shown 
in Figure 5A. Anti–miR-31 transfectants had significantly fewer 
colonies than the controls, with P = 0.018 for ED-1 cells and 
P = 0.0002 for ED-2 cells.
To examine whether the observed repression of lung cancer 
cell clonal growth was associated with repression of in vivo 
tumorigenicity, we injected syngeneic FVB mice via tail vein 
with ED-1 cells (see Methods) that were transiently transfected 
with anti–miR-31 to achieve knockdown of miR-31. Results were 
compared with those for control transfectants. Twenty-five days 
after tail vein injections, lung lesions were scored. As shown in 
Figure 5B, ED-1 cells transfected with anti–miR-31 produced 
significantly fewer (P ≤ 0.05) lung lesions as compared with 
ED-1 control transfectants. Knockdown of miR-31 by transient 
transfection persisted for 5–6 days, while the outgrowth of lung 
lesions occurred typically by 7–15 days after injection (data not 
shown). To examine whether higher anti–miR-31 transfection 
dosages produced greater repression of miRNA-31 expression 
or in vivo tumorigenicity, we transfected ED-1 cells with 4-fold-
higher dosages of anti–miR-31 or anti–miR control oligonucle-
otides than those used in Figure 5B. Compared with controls 
and with the results of the anti–miR-31 ED-1 transfection 
experiment shown in Figure 5B, findings revealed that a higher 
anti–miR-31 transfection dosage reduced miR-31 expression 
and in vivo lung cancer tumorigenicity to a greater extent than 
the lower dosage (Supplemental Figure 2).
Bioinformatic mRNA targets. To study mechanisms responsible 
for lung cancer growth suppression caused by miR-31 knock-
down, we performed bioinformatic analyses to search for miR-31 
target mRNAs. TargetScan 4.1, PicTar, and miRanda were each 
used to independently predict miR-31 targets. It is known that 
each miRNA can affect multiple targets via distinct mechanisms 
(29). Given this, attention focused on identification of candi-
date tumor-suppressive genes that could exert miR-31 growth-
inhibitory effects. Several candidates were highlighted, including 
LATS2, PPP2R2A, Frizzled homolog 3 (FZD3), Sprouty-related, 
EVH1 domain containing 1 (SPRED1), Sprouty homolog 4 
(SPRY4), AXIN1 upregulated 1 (AXUD1), and DICER1. These 
candidate targets were validated based on (a) an inverse rela-
tionship between miR-31 and their expression in murine as well 
as human lung cancers; (b) experiments revealing that in vitro 
growth inhibition by engineered miR-31 repression was antago-
Figure 4
Regulation of miR-31 expression affects lung cancer cell proliferation. (A) Proliferation of ED-1 and ED-2 murine lung cancer cells and H23 and 
H226 human lung cancer cells was suppressed by engineered miR-31 knockdown after anti–miR-31 transfection, but murine C10 pulmonary 
epithelial cell proliferation was suppressed to a lesser extent. BEAS-2B human immortalized bronchial epithelial cell growth was not significantly 
reduced by this transfection. *P < 0.05, **P < 0.01, ***P < 0.0001. The lower panel displays results of real-time RT-PCR assays that confirm 
miR-31 repression; ***P < 0.0001. (B) Significant repression of ED-1 and ED-2 cell growth caused by anti–miR-31 was antagonized by transfec-
tion of pre–miR-31 at 48 hours after anti–miR-31 transfection. The left panels display proliferation, and the right panels present the real-time 
RT-PCR assay results confirming the expected repressed levels of these miR-31 transfectants as compared with control transfectants (Ctrl). 
***P < 0.0001. Error bars indicate SD.
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nized by knockdown of a putative target; and (c) evidence for 
direct binding in 3′-UTR luciferase reporter assays. The miR-31 
targets sought were those that were repressed by forced miR-31 
overexpression and augmented by its engineered knockdown 
in lung cancer cells. Among these candidates, only LATS2 and 
PPP2R2A satisfied this criterion (Figure 6, A and B) and the oth-
ers. All 6 cell lines (ED-1, ED-2, C10, H23, H226, and BEAS-2B) 
were independently examined in these analyses, and studies 
yielded concordant results.
LATS2, human large tumor suppressor 2 (also known as KPM), 
is a member of the LATS tumor suppressor family (30). LATS2 
was identified as exerting tumor-suppressive effects by inhibition 
of the G1/S cell cycle transition (31). LATS2 was also found to 
be a target of miR-372 and miR-373 in testicular germ cell can-
cers (32). PPP2R2A, also known as protein phosphatase 2A B55 
subunit, was previously uncovered as a tumor suppressor that 
induced apoptosis (33, 34).
LATS2 and PPP2R2A are direct miR-31 targets. Luciferase binding 
assays were conducted using pEZX-MT01 luciferase constructs 
to determine whether miR-31 suppressed LATS2 and PPP2R2A 
through direct binding to their respective 3′-UTRs. Wild-type 
and mutant 3′-UTRs of LATS2 or PPP2R2A were independently 
cloned into this vector containing the firefly luciferase gene, 
with the control Renilla luciferase gene driven by the CMV pro-
moter. The ratios of firefly and Renilla luciferase signals reflect-
ed the degree of 3′-UTR binding of these targets.
The luciferase signals for wild-type 3′-UTR sequences of both 
LATS2 and PPP2R2A were repressed by cotransfection of pre–
miR-31 in ED-1 cells and increased by cotransfection of anti–miR-
31. In contrast, engineered mutations of the miR-31–binding site 
antagonized these effects (Figure 6, C and D). These results indi-
cated that miR-31 can directly bind to the 3′-UTR sequences of 
LATS2 and PPP2R2A.
To determine whether LATS2 and PPP2R2A were engaged in 
miR-31–mediated growth suppression, we individually knocked 
down these target genes by siRNAs in ED-1 cells 48 hours after 
initial anti–miR-31 transfection to learn whether this would 
repress miR-31 effects. As expected, siRNA-mediated knock-
down of either LATS2 or PPP2R2A antagonized growth sup-
pression caused by engineered miR-31 repression (Figure 7A). 
Two different siRNAs were used to target LATS2 as well as to 
target PPP2R2A. Each study was conducted in triplicate, and the 
results were replicated in 2 independent experiments. Compared 
with control siRNAs, LATS2-targeting siRNAs and PPP2R2A-
targeting siRNAs each repressed these respective mRNAs to lev-
els 5%–6% of the basal expression levels as measured by real-time 
RT-PCR assays (Figure 7B). These results revealed that repres-
sion of LATS2 and PPP2R2A antagonized growth suppression 
caused by miR-31 knockdown and functionally validated them 
as miR-31 growth-regulatory targets. Similar results were inde-
pendently obtained in experiments with ED-2 cells, as shown 
in Figure 7, C and D. Similar assays were conducted using the 
human lung cancer cell lines H226 and H23. As shown in Sup-
plemental Figure 3, these results were concordant with findings 
obtained in murine lung cancer cells.
LATS2 and PPP2R2A expression in lung cancers. Since miR-31 was 
overexpressed in both murine cyclin E–driven transgenic lung 
cancers and human lung cancer tissues, we next examined wheth-
er LATS2 and PPP2R2A were each repressed in these lung can-
cers relative to adjacent normal lung tissues. Real-time RT-PCR 
assays were conducted on murine cyclin E–driven transgenic lung 
adenocarcinomas and adjacent normal lung tissues, as well as in 
previously examined paired human normal-malignant lung tis-
sues (17). LATS2 and PPP2R2A were each basally repressed in 
these murine transgenic lung cancers, with mRNA levels signifi-
cantly reduced as compared with those in adjacent normal lung 
tissues, as shown in Figure 8, A and B. As expected, LATS2 and 
PPP2R2A expression profiles were also repressed in all examined 
human lung cancers relative to adjacent normal tissues, as shown 
Figure 5
Repression of miR-31 expression significantly affects murine lung can-
cer clonal growth and tumorigenicity. (A) Colony formation was sup-
pressed in ED-1 and ED-2 murine lung cancer cells relative to controls 
by engineered knockdown of miR-31 through transient anti–miR-31 
transfection. The stained colonies are displayed in the bottom row. (B) 
Repression of in vivo lung tumorigenicity of the indicated transfected 
ED-1 cells after FVB mouse tail vein injections. The bars represent 
the percentage of lung lesion numbers for anti–miR-31 transfection 
of ED-1 cells relative to mice injected via tail vein with anti–miR-ctrl 
transfected ED-1 cells. Forty mice in total were used, and each group 
had 10 mice, with results pooled from 2 independent experiments, as 
described in Methods. *P ≤ 0.05, **P < 0.01. Error bars indicate SD 
in A and SEM in B.
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in Figure 8, C and D. These results establish that expression pro-
files were concordant for miR-31 and its target mRNAs in both 
murine and human lung cancers.
Clinical associations between miR-31 and target genes. To compre-
hensively examine the clinical association between miR-31 and its 
target genes (LATS2 and PPP2R2A), we examined a human lung 
cancer tissue microarray and mRNA isolated from correspond-
ing cases using samples from patients identified through the New 
Hampshire State Cancer Registry and the Dartmouth-Hitchcock 
Tumor Registry, as described in Methods. We conducted assays on 
this tissue microarray to examine cyclin E immunohistochemical 
expression and ISH analyses for miR-31. We also performed real-
time RT-PCR assays on mRNA isolated from these tissues to 
determine levels of LATS2 and PPP2R2A. Cyclin E and miR-31 
expression levels were significantly associated with each other 
(P < 0.001). According to a previously optimized scoring system 
(35), low miR-31 expression was associated with low levels of 
cyclin E, and intermediate and high miR-31 levels were associ-
ated with higher cyclin E levels (Figure 9A). Logistic regression 
analyses were used to explore the association between miR-31 
expression profiles in malignant as well as normal lung tissues. 
Enhanced miR-31 expression was more frequent in malignant as 
compared with normal lung tissues, as shown in Figure 9B. This 
difference was particularly apparent in subjects with squamous 
cell carcinoma (P = 0.048). Real-time RT-PCR assays performed on 
mRNA harvested from the same cases also confirmed that levels of 
LATS2 and PPP2R2A were repressed in lung cancers as compared 
with normal lung tissues (Figure 9C). These results uncovered a 
close relationship between cyclin E and miR-31 expression as well 
as between miR-31 and expression of its target genes LATS2 and 
PPP2R2A in human lung cancers.
Discussion
It is known that miRNAs are key regulators of gene expression and 
that these are aberrantly expressed in diverse cancers, including lung 
cancer (5, 9, 10, 17). Murine cyclin E–driven transgenic lines were 
studied as tools that recapitulated key features of human lung carci-
nogenesis (18). A set of miRNAs (miR-136, miR-376a, and miR-31) 
was prominently overexpressed in murine lung cancers versus adja-
cent normal lung tissues according to microarray and real-time 
RT-PCR assays. These miR-31 expression profiles were confirmed 
in murine and human lung tissues by real-time PCR and ISH assays 
(Figures 1 and 2 and Figure 3). Expression profiles for these high-
lighted miRNAs in murine malignant versus normal lung tissues 
were similar to those in a paired human normal-malignant lung tis-
sue bank (Figure 3B). Engineered knockdown of miR-31 repressed 
proliferation of both murine and human lung cancer cell lines, but 
modest or no significant growth inhibition was observed in immor-
talized pulmonary epithelial cell lines, indicating differential inhib-
itory effects in these distinct cell contexts (Figure 4). Engineered 
repression of miR-31 also reduced lung cancer cell clonal growth 
and in vivo tumorigenicity in the lung (Figure 5). Notably, this 
repression of in vivo tumorigenicity depended on dose-dependent 
reduction of miR-31 expression (Supplemental Figure 2).
Figure 6
LATS2 and PPP2R2A are miR-31 target mRNAs. Real-time RT-PCR assays confirmed that (A) LATS2 and (B) PPP2R2A expression levels 
were each downregulated by pre–miR-31 and upregulated by anti–miR-31 transfections independently performed in ED-1, ED-2, C-10, H23, 
H226, and BEAS-2B cells. All transfectant groups in A and B had P values less than 0.0001. The described 3′-UTR luciferase binding assays 
confirmed that miR-31 binds to the wild-type 3′-UTR sequences of (C) LATS2 and (D) PPP2R2A in ED-1 cells. Cotransfection of pre–miR-31 
significantly reduced the luciferase levels, and cotransfection of anti–miR-31 increased them. In contrast, a mutated miR-31–binding site (Mut) 
within these 3′-UTRs antagonized these effects. *P < 0.05, **P < 0.01. Error bars indicate SD.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 120   Number 4   April 2010 1305
In studying potential mechanisms engaged, we identified 
LATS2 and PPP2R2A as tumor-suppressive mRNA targets by 
bioinformatic analyses and functional as well as binding assays. 
Both target mRNAs were downregulated by miR-31 (Figure 6). 
Knockdown of miR-31 augmented LATS2 and PPP2R2A expres-
sion and conferred growth inhibition, which was antagonized 
by siRNA-mediated knockdown of either LATS2 or PPP2R2A 
(Figure 7). Expression levels of LATS2 and PPP2R2A were each 
basally repressed in both murine and human lung cancer cells 
(Figure 8). Clinical associations between miR-31 and its target 
genes, LATS2 and PPP2R2A, were uncovered (Figure 9 and data not 
shown). Taken together, these findings revealed a set of miRNAs 
prominently overexpressed in lung cancers, and of these species, 
only miR-31 was functionally required to drive lung cancer cell 
growth and tumorigenicity. These findings build on previously 
highlighted growth-suppressive miRNAs in lung cancer (17) by 
revealing specific miRNAs overexpressed in lung cancer. We pro-
pose that miR-31 acts as an oncomir in this context by negatively 
regulating specific tumor suppressors. This view is supported 
by miR-31 knockdown experiments in which its tumor-suppres-
sive targets, LATS2 and PPP2R2A, were derepressed. Thus, the 
miR-31/LATS2/PPP2R2A pathway constitutes a previously unrec-
ognized growth regulator of lung cancer.
Lung cancer is the leading cause of cancer mortality for men and 
women in the United States (8). An improved understanding of 
lung cancer biology and therapy is needed. This study advances 
prior work (6, 7, 9–17) by uncovering the key role played by miR-31 
in regulating lung carcinogenesis and by finding functionally rel-
evant mRNA targets. Future work should build on these findings 
by precisely determining how these tumor-suppressive pathways 
are activated by miR-31 repression and how augmented LATS2 
and PPP2R2A expression confers repression of lung cancer growth 
in vitro and in vivo. Preliminary studies indicated that changes in 
cell cycle regulation may confer some of the observed anti-neoplas-
tic effects (data not shown).
The miRNAs are promising anti-neoplastic agents (36). It 
is appealing to consider testing an inhibitor to a functionally 
important oncogenic miRNA (such as miR-31) for treatment of 
transgenic lung cancer models or other murine cancer models 
to learn whether this would elicit antitumor responses. In this 
regard, the wild-type and proteasome degradation–resistant 
cyclin E–transgenic lines studied here should prove useful for 
prioritizing miRNAs for further study as clinical anti-neoplas-
tic agents. Perhaps combination therapy with pharmacologi-
cally optimized inhibitors of miR-31 will confer desired anti-
tumorigenic effects. The miR-17-92 and miR-200/429 families 
are also important in lung cancer biology (37, 38), and their 
inhibitors might cause anti-neoplastic effects. This might 
involve both knockdown of an oncomir and overexpression of a 
tumor-suppressive miRNA in lung cancer. Successful preclinical 
studies would set the stage for clinical targeting of highlighted 
miRNAs. Notably, in vitro and in vivo reports of LNA-mediated 
silencing of miRNAs support the use of LNAs for targeting spe-
cific miRNAs (39, 40).
Figure 7
The proliferation of murine lung cancer cells following regulated expression of miR-31, LATS2, or PPP2R2A. The growth of (A) ED-1 cells and 
(C) ED-2 cells was suppressed by transfection of anti–miR-31. This was antagonized by either LATS2- or PPP2R2A-targeting siRNA trans-
fections performed 48 hours after anti–miR-31 transfection. Two independent siRNAs were each used to target LATS2 as well as PPP2R2A. 
*P < 0.05, **P < 0.01, ***P < 0.0001. The mRNA levels of Lats2 and Ppp2r2a are presented for the indicated transfectants in (B) ED-1 cells and 
(D) ED-2 cells following real-time RT-PCR assays. All results were normalized to the anti–miR-ctrl and the negative control siRNA transfectants. 
***P < 0.0001. Error bars indicate SD.
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In summary, miR-136, miR-376a, and miR-31 were prominent-
ly overexpressed miRNAs in murine and human lung cancers rel-
ative to adjacent normal lung tissues. Engineered repression of 
miR-31, but not the other 2 miRNAs, caused marked repression 
of lung cancer growth in vitro and in vivo. Notably, LATS2 and 
PPP2R2A were targeted by miR-31, providing a likely mechanism 
responsible for the observed growth inhibition through a previ-
ously unrecognized regulation of tumor-suppressive pathways. 
It is intriguing to speculate that use of miR-31 as a biomarker 
would improve diagnosis or classification of human lung cancer 
and even provide prognostic information. In this regard, prelimi-
nary data indicated a trend toward poor prognosis in lung can-
cer cases exhibiting high miR-31 expression (data not shown). 
Conceivably, targeting of miR-31 by anti-miR oligonucleotides 
would form the basis for a novel strategy to treat or even prevent 
different types of lung cancers. Indeed, evidence indicated that 
clinical associations exist between miR-31 and cyclin E in NSCLC 
subtypes beyond adenocarcinoma, where these associations were 
first found. Taken together, these findings indicate that miR-31 
acts as an oncogenic miRNA in lung cancer by conferring repres-
sion of specific tumor suppressors.
Methods
Transgenic lung tissues. Murine cyclin E–transgenic lines that exhibit pre-
malignant and malignant (adenocarcinoma) lung lesions were previously 
described (18). Those studied here included human SP-C–driven wild-type 
cyclin E–transgenic (line 2) and proteasome degradation–resistant (line 4) 
lines (18). Adenocarcinomas and adjacent histopathologically normal 
lung tissues were individually harvested from age- and sex-matched mice 
and immediately placed in RNAlater (Ambion). Total RNA was isolated 
using established techniques (17, 35, 41) for miRNA expression arrays. 
Formalin-fixed and paraffin-embedded transgenic lung tissues were har-
vested (18) and used for ISH assays.
Human lung tissues. Paired human normal and malignant lung tissues 
were obtained after review and approval by Dartmouth’s Institutional 
Review Board (IRB). Patient identifying information was not linked to 
this tissue bank consecutively accrued over 8 years at Dartmouth-Hitch-
cock Medical Center (17).
RNA isolation and miRNA arrays. The RNA isolation and miRNA array 
procedures were described previously (17). In brief, total RNA was isolated 
from cell lines and lung tissues with TRIzol reagent (Invitrogen) and was 
3′-end labeled using T4 RNA ligase to couple Cy3-labeled RNA linkers. 
Labeled RNA was hybridized to LNA microarrays overnight at 65°C in 
a hybridization mixture containing 4× sodium chloride sodium citrate 
(SSC) (1× SSC: 150 mM sodium chloride and 15 mM sodium citrate), 
0.1% SDS, 1 μg/μl herring sperm DNA, and 38% formamide. Slides were 
washed 3 times in 2× SSC, 0.025% SDS at 65°C, 3 times in 0.8× SSC, and 
3 times in 0.4× SSC at room temperature. Each RNA sample was indepen-
dently hybridized twice. There were 4 probe sets used for each miRNA. 
Only concordant hybridization results were scored. Microarrays were 
scanned using an ArrayWorx scanner (Applied Precision). Images were 
analyzed using GridGrinder (http://gridgrinder.sourceforge.net/), and 
background-subtracted spot intensities were normalized using variance 
stabilization normalization (35). The miRNAs selected for in-depth study 
showed statistically significant expression differences in both murine and 
human normal versus malignant lung tissues.
Real-time RT-PCR assays. The miRNA RT-PCR assays were performed 
using the TaqMan miRNA Reverse Transcription Kit (Applied Biosys-
Figure 8
Validation of LATS2 and PPP2R2A expression profiles by real-time RT-PCR assays performed on RNA isolated from the indicated murine cyclin E– 
transgenic lines and from the paired human normal-malignant lung tissues. Real-time RT-PCR assays for (A) LATS2 and (B) PPP2R2A were 
performed. Results were normalized to expression within nontransgenic FVB mouse lung tissues. Real-time RT-PCR assays for (C) LATS2 and 
(D) PPP2R2A were independently performed on paired human normal-malignant lung tissues. Results were normalized to expression in normal 
human lung tissues. In all groups, P values were less than 0.001. Error bars indicate SD.
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tems) and the 7500 Fast Real-Time PCR System (Applied Biosystems) 
for quantitative miRNA detection, and each miRNA TaqMan PCR 
probe was purchased from Applied Biosystems, as described previ-
ously (17). The real-time RT-PCR assays were performed using the 
7500 Fast Real-Time PCR System for quantitative mRNA detection 
and with iTaq Fast SYBR Green Supermix (Bio-Rad). The primers for 
real-time PCR were human GAPDH: 5′-ATGGGGAAGGTGAAGGTCG-
3′ (forward) and 5′-GGGGTCATTGATGGCAACAATA-3′ (reverse); 
human PPP2R2A: 5′-TCGGATGTAAAATTCAGCCA-3′ (forward) and 
5′-CATGCACCTGGTATGTTTCC-3′ (reverse); human LATS2: 5′-
CAGATTCAGACCTCTCCCGT-3′ (forward) and 5′-CTTAAAGGCG-
TATGGCGAGT-3′ (reverse); mouse GAPDH: 5′-AGGTCGGTGTGAAC-
GGATTTG-3′ (forward) and 5′-TGTAGACCATGTAGTTGAGGTCA-3′ 
(reverse); mouse LATS2: 5′-AGCAGATTGTGCGAGTCATC-3′ (forward) 
and 5′-GTGGTAGGATGGGAGTGCTT-3′ (reverse); mouse PPP2R2A: 5′-
TAAGAGAGCGGTCCATTGTG-3′ (forward) and 5′-ACAGCTTTCTC-
CATGAGGCT-3′ (reverse).
ISH assays. ISH assays were performed as in previous work (17, 35). 
In brief, slides were prehybridized in hybridization solution (50% for-
mamide, 5% SSC, 500 μg/ml yeast tRNA, and 1% Denhardt’s solution) at 
50°C for 30 minutes. Ten picomoles of the desired FITC-labeled, LNA-
modified DNA probes (Integrated DNA Technologies) complementary 
to specific miRNAs and/or biotinylated unmodified DNA probes against 
18S rRNA were added and hybridized for 2 hours at a temperature 
20–25°C below the calculated melting temperature of the LNA probe. 
After stringent washes, a tyramide signal amplification (TSA) reaction 
was carried out using the GenPoint Fluorescein kit (DakoCytomation) 
and the manufacturer’s recommended procedures and with the substi-
tution of streptavidin/HRP (Invitrogen) for detection of biotinylated 
probes. Slides were mounted with Prolong Gold solution (Invitrogen). 
This methodology was applied to the tissue array developed from the 
New Hampshire State Cancer Registry and the Dartmouth-Hitchcock 
Tumor Registry. The miR-31 levels were scored as low, medium, or high 
using a previously described ISH scoring system (35).
Cell lines. The murine lung cancer cell lines (ED-1 and ED-2) were derived 
from wild-type cyclin E– and proteasome degradation–resistant cyclin E– 
transgenic mice, respectively (17). The C10 murine alveolar type II epithe-
lial cell line and H226, H23, HOP62, H522, and A549 human lung cancer 
cell lines were each purchased from ATCC. BEAS-2B immortalized human 
bronchial epithelial cells were provided by Curtis C. Harris (NIH and 
National Cancer Institute, Bethesda, Maryland).
Tissue culture. ED-1, ED-2, H226, H23, HOP62, H522, and A549 cells 
were each cultured in RPMI 1640 medium with 10% FBS and 1% antibiotic 
and antimycotic solution in a humidified incubator at 37°C in 5% CO2. 
C10 cells were cultured in CMRL 1066 medium (Life Technologies) with 
10% FBS, 2 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml strep-
tomycin (18). BEAS-2B cells were cultured in serum-free LHC-9 medium 
(Invitrogen), as reported (42).
Transient transfection. ED-1, ED-2, C10, H226, H23, and BEAS-2B cells 
were individually plated subconfluently onto each well of 6-well tissue 
culture plates or 10-cm dishes 24 hours before transfection. Transient 
transfection of pre-miR miRNA precursors and/or anti-miR and control 
oligonucleotides (anti–miR-ctrl or pre–miR-ctrl) (Ambion) at a final con-
centration of 50 nM (or 200 nM) was accomplished with siPORT NeoFX 
reagent (Ambion) using previously optimized methods (17). The siRNA 
transfections were conducted following the same procedure as for a pre-
miR and used at a final concentration of 25 nM. The Silencer Select Pre-
designed siRNAs were purchased from Applied Biosystems, and murine 
Figure 9
Clinical associations between miR-31 expression profiles and those of its target genes, LATS2 and PPP2R2A, were explored as described 
in Methods. (A) Associations between cyclin E immunohistochemical expression and miR-31 levels were significant. (B) Augmented miR-31 
expression was more frequent in malignant as compared with normal lung tissues. (C) LATS2 and PPP2R2A were significantly downregulated 
in lung cancers as compared with adjacent normal lung tissues. “Other” indicates lung cancer histopathologies. Error bars indicate SEM in A 
and SD in B and C. *P < 0.05, ***P < 0.0001.
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LATS2 siRNAs (catalog 4390771 with siRNA ID s78350 and s78351), 
murine PPP2R2A siRNAs (catalog 4390771 with siRNA ID s90396 and 
s90395), human LATS2 siRNA (catalog 4392420 with siRNA ID s25503 
and s25504), human PPP2R2A siRNA (catalog 4390824 with siRNA ID 
s608 and s609), and a negative control siRNA (catalog 4390843) were also 
used in these experiments. Logarithmically growing transfectants were har-
vested for independent immunoblot, proliferation, apoptosis, and trypan 
blue viability assays, as described below.
Proliferation and colony formation assays. The CellTiter-Glo proliferation 
assay (Promega) was used along with previously optimized methods (17). 
The colony formation assay was performed as in previous work (42) with 
2.5 × 102 ED-1 cells or 5 × 102 ED-2 cells or the indicated transfectants 
independently plated onto 10-cm tissue culture plates. After 10 days, 
visible colonies were fixed and stained with Diff-Quik solution (Baxtor) 
and quantified using the Col Count instrument (Oxford Optronix), as 
previously described (17).
Apoptosis assay. Trypan blue viability assays were performed as described 
previously (28). Apoptosis was scored by annexin V:FITC positivity as 
detected by flow cytometry using the Annexin V assay kit (AbD Serotec) 
and following the vendor’s recommended protocol.
In vivo tumorigenicity and statistical assays. Early passages of ED-1 cells were 
harvested in PBS supplemented with 10% mouse serum (Invitrogen), and 
106 cells of each transfectant of this cell line were individually injected 
into tail veins of each respective FVB syngeneic mouse. In each experimen-
tal arm, 10 mice tail vein–injected with control transfected ED-1 cells and 
10 mice tail vein–injected with miR-31–knockdown ED-1 transfectants 
were used (the final concentrations of anti–miR-31 and anti–miR-ctrl 
were each 50 nM). With a replicate experiment, a total of 40 mice were 
examined. After injection (17 days), mice were sacrificed according to 
an IACUC-approved protocol at Dartmouth, and harvested lung tissues 
were formalin fixed, paraffin embedded, sectioned, and H&E stained for 
histopathologic analyses using optimized methods (18). Histopathologic 
sections were scored for lung tumors by a pathologist who was unaware 
of the treatment arms being analyzed. The log transformation of these 
data was used to eliminate the skewness of counts, with the subsequent 
application of the 2-tailed t test for comparison of the number of lung 
lesions in the FVB mice injected with anti–miR-ctrl versus anti–miR-31 
transfectants. The difference was scored as statistically significant if 
the P value was 0.05 or less. For an independent statistical analysis, the 
likelihood ratio test was used, with the assumption that counts follow a 
Poisson distribution. Computations were conducted using the statistical 
package S-Plus 6.1 (Insightful Inc.).
The dose-dependent in vivo tumorigenicity assays (Supplemental Figure 2) 
were conducted using the same experimental procedures as described 
above. For each experimental arm, up to 6 FVB mice were used. In these 
respective experiments, 50 nM (1-fold) and 200 nM (4-fold) final dosages 
of anti–miR-31 or anti–miR-ctrl were used. The same tumorigenicity scor-
ing methods and statistics were used in each experiment.
Immunohistochemistry assays. The immunohistochemistry assays were 
conducted on tissue microarrays (described below) to detect and score 
cyclin E immunohistochemical expression profiles using previously 
optimized methods (18).
Bioinformatics. The following online software programs were used: 
TargetScan 4.1 (http://targetscan.org/vert_40/), Pictar (http://pictar.
mdc-berlin.de/), and miRanda (http://cbio.mskcc.org/cgi-bin/mirna-
viewer/mirnaviewer.pl).
3′-UTR luciferase binding assays. Murine LATS2 (MmiT031281-MT01), 
PPP2R2A (MmiT035372-MT01), and control (CmiT000001-MT01) 
3′-UTR luciferase constructs were purchased from GeneCopoeia. The 
underlined sequences indicate the miR-31–binding site for LATS2 (TCTT-
GCC) and PPP2R2A (TGCACCATCTTGCC). These were mutated using 
the QuickChange XL Site-Directed Mutagenesis Kit (Stratagene). The 
resulting mutant binding sites for LATS2 (TCTGCGG) and for PPP2R2A 
(TGCACCATCTGCGG) are each indicated in bold.
Transient transfection of luciferase plasmids with pre-miR miRNA 
precursors and/or with an anti-miR inhibitor was conducted using Lipo-
fectamine 2000 (Invitrogen) at final concentrations of 250 pg/μl (luciferase 
plasmid) and 50 nM (pre-miR or anti-miR). The luciferase signal was read 
by a TD-20/20 Luminometer (Turner Biosystems).
New Hampshire State Cancer and Dartmouth-Hitchcock Tumor Registries. The 
New Hampshire State Cancer Registry and the Dartmouth-Hitchcock 
Tumor Registry were used to identify persons from 2005 to 2007 who 
had received a clinical diagnosis of lung cancer. Eligible cases had histo-
logically confirmed primary incident lung cancer, were between 30 and 
74 years of age, resided in one of the 10 study counties, were alive at first 
contact, had a working telephone number, and were able to communicate 
in English. Of the eligible cases, 5% could not be reached because of an 
inaccurate address or phone number, 11% were too ill to be interviewed, 
and 22% refused to participate, which yielded a 61% participation rate. Sur-
vival status was determined using a combination of the National Death 
Index (deaths through 2006) and the Social Security Death Index (deaths 
through September 17, 2009). Tumor stage and histology were obtained 
from the State Cancer Registry. The signed consents were obtained to 
allow access to tumor specimens from these cases, and these studies were 
reviewed and approved by the Dartmouth IRB for human subjects. A mas-
ter tissue microarray block was constructed containing tissue samples 
representing 84 subjects who had lung biopsies. The stage distribution of 
these cases was 50% stage I, 17% stage II, 20% stage III, 7% stage IV, and 
5% unknown. The histopathology indicated 52% adenocarcinomas, 28% 
squamous cell cancers, 7% large cell cancers, 4% neuroendocrine cancers, 
and 9% unknown. The cases had a median age of 62, and 94% were current 
or former smokers with a median of 45 pack-years of smoking. These char-
acteristics were similar to those of the overall study case group.
Note added in proof. After submission of our manuscript, a role for miR-31 
in regulating breast cancer metastasis was reported (43).
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